IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

SCHUFF INTERNATIONAL, INC. : CONSOLIDATED
STOCKHOLDERS LITTGATION : C.A. No. 103

STOCKHOLDERS LITIGATION : C.A. No. 10323-VCZ

Chancery Courtroom No. 12C Leonard L. Williams Justice Center 500 North King Street Wilmington, Delaware Thursday, February 13, 2020 1:35 p.m.

BEFORE: HON. MORGAN T. ZURN, Vice Chancellor.

SETTLEMENT HEARING

CHANCERY COURT REPORTERS Leonard L. Williams Justice Center 500 North King Street - Suite 11400 Wilmington, Delaware 19801

(302) 255-0522

```
1
    APPEARANCES:
 2
         SETH D. RIGRODSKY, ESQ.
         Rigrodsky & Long, P.A.
 3
                 -and-
         TIMOTHY J. MACFALL, ESQ.
 4
          of the New York Bar
         Rigrodsky & Long, P.A.
 5
                 -and-
         DONALD J. ENRIGHT, ESQ.
 6
         ELIZABETH K. TRIPODI, ESQ.
         of the District of Columbia Bar
 7
         Levi & Korsinsky, LLP
           for Plaintiff
 8
         J. PETER SHINDEL, JR., ESQ.
 9
         MATTHEW L. MILLER, ESQ.
         STEPHEN C. CHILDS, ESQ.
10
         Abrams & Bayliss LLP
            for Defendants Philip A. Falcone, Keith M.
11
           Hladek, and HC2 Holdings, Inc.
12
         AARON M. NELSON, ESQ.
         Heyman, Enerio, Gattuso & Hirzel LLP
13
            for Defendant Paul Voigt
14
         STEVEN T. MARGOLIN, ESQ.
         Greenberg Traurig, LLP
15
            for Defendant D. Ronald Yagoda
16
         PETER B. LADIG, ESQ.
         Bayard, P.A.
17
            for Defendants James Rustin Roach and
           Michael R. Hill
18
         ROBERT J. KRINER, JR., ESQ.
19
         TIFFANY J. CRAMER, ESQ.
         Chimicles Schwartz Kriner & Donaldson-Smith LLP.
20
                 -and-
         DANIEL W. KRASNER, ESQ.
21
         of the New York Bar
         Wolf Haldenstein Adler Freeman & Herz LLP
22
            for Objector Fair Value Investments
23
            Incorporated
24
                                          ... (cont'd)
```

```
3
 1
    APPEARANCES (cont'd):
         MARCUS E. MONTEJO, ESQ.
 2
         Prickett, Jones & Elliott, P.A.
 3
            for Interested Party AB Value Partners, L.P
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```

THE COURT: Good afternoon, everyone. 1 2 VARIOUS COUNSEL: Good afternoon, Your 3 Honor. THE COURT: Lots of folks to introduce 4 5 me to. So whoever wants to start. 6 MR. RIGRODSKY: Good afternoon, Your 7 Seth Rigrodsky from Rigrodsky & Long, 8 co-counsel for plaintiff. I rise to introduce my 9 co-counsel, Don Enright of Levi & Korsinsky, who will 10 be presenting for the plaintiff today. With me at 11 counsel table is my partner, Timothy MacFall, and also 12 of Levi & Korsinsky, Elizabeth Tripodi. 13 THE COURT: Thank you. Welcome. 14 MR. SHINDEL: Good afternoon, Your 15 Honor. Pete Shindel from Abrams & Bayliss on behalf 16 of the HC2 defendants. I'm joined today at counsel 17 table by my colleagues Matt Miller and Stephen Childs. 18 THE COURT: Hello. 19 MR. KRINER: Good afternoon, Your 20 Honor. Robert Kriner on behalf of Fair Market 21 Investments, the objector. With me at counsel table 22 is my colleague, Tiffany Cramer, from my firm. 23 with me is Mr. Gary Lutin, my client, the chairman of

Fair Market, and my co-counsel, Mr. Dan Krasner from

24

```
Wolf Haldenstein.
 1
 2
                    THE COURT: Thank you.
 3
                    MR. MONTEJO: Good afternoon, Your
 4
           Marcus Montejo, Prickett, Jones & Elliott, on
 5
    behalf of AB Value. I don't have anybody to
 6
    introduce, but I didn't want to be left out.
 7
                    THE COURT: All right. Good to see
 8
    you.
 9
                    And last, but not least.
10
                    MR. LADIG: Good afternoon, Your
11
    Honor. Peter Ladig from Bayard on behalf of the
12
    defendants Michael Hill and Rustin Roach.
13
                    THE COURT: Thank you.
14
                    MR. MARGOLIN: Continuing the parade,
15
    Your Honor, Steven Margolin from Greenberg Traurig on
16
    behalf of defendant Mr. Ron Yagoda.
17
                    THE COURT: Thank you.
18
                    MR. NELSON: Good afternoon, Your
19
    Honor. Aaron Nelson of Heyman Enerio Gattuso & Hirzel
20
    on behalf of Mr. Paul Voigt.
2.1
                    THE COURT: Thank you. Welcome,
22
    everyone.
23
                    Plaintiff, did you want to go first?
24
                    MR. ENRIGHT: Please, Your Honor.
```

THE COURT: All right. Thank you.

You may proceed.

MR. ENRIGHT: Good afternoon, Your Honor. Donald Enright of Levi & Korsinsky appearing on behalf of plaintiff Mark Jacobs and the plaintiff class. We are here today upon plaintiff's motion for final approval of the proposed settlement of the action that's before Your Honor.

I would like to note that since we are doing introductions, Mark Jacobs, the plaintiff, is here. Mr. Jacobs, do you want to say hello?

After five years of litigation, involving the review of over 114,000 pages of documents, adversarial depositions, and prolonged and extremely contentious negotiations, plaintiff has achieved a resolution of the action that more than doubles the price of the original tender offer that gave rise to this litigation.

The class members who tendered their shares will receive an additional \$35.95 per share, less any fees and expenses that the Court awards. And that's compared to the original tender offer price of \$31.50.

This price bump is a premium of more

than 114 percent over the October 2014 tender offer price. And to my knowledge, that is the largest percentage increase in a recovery in Delaware merger class action history. We have been unable to locate any settlements that achieved a better percentage increase than this. And it is, candidly, a result that I am enormously proud of. We have worked very hard to try to get here.

2.1

The settlement also gives the company's minority stockholders, those who did not tender in the tender offer, the opportunity to tender their common stock for \$67.45 per share, again, before the fees are subtracted.

From the outset, plaintiff contended that the buyout was a unitary transaction under well-established Delaware law, with all shareholders of the company suffering the same injury and damages. The buyout was supposed to have been comprised of a tender offer and a subsequent cash-out short form merger.

Plaintiff's claims asserted that HC2 was obligated to complete the short form merger when it reached 90 percent ownership of Schuff stock, shortly after the tender offer was completed, and that

it wrongly reneged on that obligation.

Accordingly, plaintiff litigated this case to achieve the same result for both the tendered and non-tendered stockholders, the fair value of Schuff stock at the close of the tender offer and when the short form merger was supposed to have been effectuated. And I will note, Your Honor, that per the discovery that we took, the -- as is publicly known, the tender offer closed on October 6th of 2014. They crossed that 90 percent ownership threshold on October 29th of 2014. So you are talking about a difference of just a couple weeks.

Consistent with these claims, the settlement provides the non-tendered stockholders with a liquidity opportunity for the same consideration, the same aggregate consideration as the tendered stockholders, at a price substantially higher than any that Schuff's common stock had ever traded at in its history before the announcement of the settlement.

THE COURT: Can you discuss the relationship of that value to the purported fair value that the objectors have raised.

23 MR. ENRIGHT: Okay. This is an 24 illiquid stock. Only 7.5 percent of it is in the

hands of anybody aside from HC2. Very, very few shares trade. It will go weeks at a time without a trade. It trades on the over-the-counter market when it does trade. But it is clearly not an efficient market. It's clearly not a liquid market.

2.1

The current fair value of these shares today is subject to debate. However, the settlement tender offer offer-to-purchase document, which was submitted to Your Honor as Exhibit D to the stipulation of settlement, contains a history of valuations and intercompany transfers of Schuff stock within the HC2 portfolio, which indicates that valuations and intercompany transfers of the stock took place in the range of over \$100 a share at various points over the last couple of years.

So the current fair value of the shares, as indicated by the disclosures in the offer to purchase, would appear, upon review of those documents, to be higher than the settlement tender offer price today.

I will get into why today's fair value price of the stock is irrelevant to our claims. Our claims stem from the value of Schuff stock at the time of the buyout in 2014. That is what our claims have

always been directed at, what they have always concerned, and what we've always been trying to achieve. The fact that the company has prospered in the interim, and its current fair value is higher, does not change the measure of damages for those claims. And that's well-established law under Gesoff and Americas Mining and a host of other decisions, all of which are set forth in our papers, as well as in defendants' response to the objections.

So to be clear, Your Honor, the settlement tender offer offer to purchase explicitly disclaims that this is intended to reflect the current fair value of the stock. It says very explicitly it is not supposed to reflect the current fair value of the stock. Rather, it is intended to provide minority stockholders with the option to receive the same aggregate consideration as the tendered stockholders if they so choose.

Now, bear in mind, Your Honor, that this is a highly illiquid stock. Since the filing of the settlement with the Court, there has been a little bit of an uptick in the trading volume of the stock. And in that intervening three months, I believe roughly 5,000 shares have changed hands. So -- and,

again, with days, and sometimes weeks at a time, passing without a single trade.

So this provides the remaining stockholders with the option, based on clear disclosure of all the facts, with the option to take this liquidity opportunity at a higher price than the stock had ever traded, if they so choose, while clearly disclosing this is not intended to be fair value, the current fair value. And instead, it's simply settlement consideration in this five-year-old litigation. And disclosing all of the recent valuations that would indicate that the price -- the fair value of the stock may be higher.

THE COURT: Why is it not the case that if the stock is so illiquid, that offering this particular liquidity event invokes more pressure for it to be fair consideration? There's no other way to get rid of the stock.

MR. ENRIGHT: Well, Your Honor, it doesn't -- it doesn't create any pressure because it simply provides an option. If they decline to take this option, then the minority stockholders remain in exactly the position that they've been in for years, which is as minority stockholders in a super majority

owned corporation. In fact, the objectors themselves have been buying shares during this period of time while it was a super majority owned company. So they were comfortable getting into this position. There's no indicator that that was something that they were unwilling to take on. So all the settlement tender offer does is provide an option.

2.1

Moreover, Your Honor, there is the possibility of a -- of another liquidity opportunity on the horizon. It's a possibility at this point.

But on February 10th, HC2 announced that they are -- that they had engaged Jefferies to seek buyers for DBMG.

Your Honor, just to be clear, I'm going to be using Schuff and DBMG sort of interchangeably today. If that ever becomes confusing to you, please let me know. It's the same company. They just changed their name in 2016.

So there's a possibility that there is another liquidity opportunity on the horizon. And that has now been widely proclaimed and disclosed to the world. The stockholders know this. So there's no danger here of this settlement tender offer being coercive because all it would be doing is providing

equal treatment for the non-tendered stockholders as the tendered stockholders, with an option to take it or not, at their election. And if they want to, they can just remain, as they've been for years, as minority stockholders in this company, receiving their dividends at a very pleasant clip.

I would note that \$17.16 in dividends have been distributed since the 2014 tender offer. That's a very nice return. So I don't think that there's any hardship here on the minority, either in terms of coercion in connection with the settlement tender offer or in remaining as current shareholders who are receiving very nice dividends.

THE COURT: So on the point of coercion, what, if anything, is the effect that the objectors comprise the majority of the minority here, and that if the company were to try and execute this, or if HC2 were to try to execute this out in the real world, they would need their buy-in and some other measures in order to pull this off without judicial scrutiny?

MR. ENRIGHT: Sure. There is no -there is no majority of the minority requirement.

There is no majority of the minority requirement in

the settlement tender offer. So if they don't tender,
that's fine.

Again, this is intended only to provide the stockholders with an opportunity to take or leave this settlement consideration, at the Court's election. And at the end of the day, Your Honor, what this really is is a distribution mechanism for a settlement, not a tender offer of the kind that was at issue in Pure Resources. It's under court supervision, and it's been negotiated by counsel who are representing the interests of these stockholders. So it's radically different from a normal self-tender of the kind that would require a majority of the minority condition.

THE COURT: And I'm not supposing that it's required. What I'm wondering is, it just strikes me that those who are objecting to this are the ones who would have a fairly significant voice in the real world if this were happening outside this courtroom.

And I'm just wondering if that comes into this at all.

MR. ENRIGHT: And they are free to give voice to their position by not tendering. I think -- frankly, I think HC2 and the defendants are essentially agnostic as far as whether or not the

objectors or any other minority stockholders tender here. Because the whole point here is simply to provide equal treatment for all of the class members. That's the whole point here, okay. That's the entire purpose of this exercise. Because we viewed this, again, as a unitary transaction where all the stockholders were affected by the same treatment.

The measure of damages is what a fair value of Schuff was in October of 2014. We have no ability whatsoever, in connection with this litigation, to make HC2 do a cash-out merger or do a tender offer at the current value because the current value isn't the subject of our litigation. They never undertook to take -- to do a cash-out merger or a short form merger in 2020.

what they did undertake to do, and what we contended that they were obligated to do, was to do that short form merger as soon as practicable after they reached that 90 percent threshold, which they did on October 29th of 2014. So because we don't have any mechanism to try to compel them to do anything today, what we have done is compel them to do what — to provide the minority stockholders with the option to take what they should have received in 2014.

If the stockholders, in light of the 1 2 appreciation in the company's value in the interim, 3 elect not to take that, that's fine. That is --4 that's their option. That's their choice. And 5 there's nothing coercing them to do otherwise. 6 There's nothing pressuring them. They remain in the 7 same exact position whether or not -- if they don't tender, they would remain in the same exact position 8 9 whether or not this settlement tender offer goes 10 forward. 11 THE COURT: Except they have now 12 released all of their claims. 13 MR. ENRIGHT: What claims, Your Honor? 14 The claims that they are -- that they are releasing 15 are claims in connection with this 2014 tender offer. 16 We are achieving full value for them on any claims 17 that they had in connection with that 2014 18 transaction. 19 The papers are extraordinarily clear 20 that the value of the stock at the time, in October of 21 2014, was, according to our experts, our consultant, 22 was \$66 and, I want to say, 61 cents. According to a 23 valuation that HC2 had done as of December 31, 2014, 24 it was \$68.99. And what we obtained for them here is

```
$67.45, 2 percent less than that December 31, 2014, valuation, and about 1 percent more than our own expert's valuation.
```

2.1

So we have obtained for them everything that they could have obtained as a result -- in terms of obtaining fair value for their stock at that 2014 time point. And that's -- and those are the only claims that are being released here, the claims arising from the 2014 transaction and claims that directly impact the settlement -- to claims arising from the settlement.

So there's -- any other claims that they might have for minority shareholder oppression, or anything like that, in the interim, those aren't being released because they don't arise from the facts and circumstances of this action, and they would be outside the scope of the release.

THE COURT: What about the fact that the stockholder class includes stockholders who actually didn't own stock back in 2014?

MR. ENRIGHT: They are successors in interest. Delaware law is perfectly clear that the claims pass with the shares.

THE COURT: What else?

MR. ENRIGHT: I'm happy to go on, Your
Honor.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

I do appreciate the colloquy because it helps focus me. I hadn't even gotten out of my introduction yet when we started. So I'll skip a lot of that.

In return for this extraordinary result, which provides a value that very closely approximates the fair value of Schuff at the time of the buyout, the defendants receive a release, as you just noted. In return, the stipulation provides, at paragraph 1(w), for the release of all claims, including unknown claims, to be candid, that any class member asserted or could have asserted based on ownership of Schuff stock during the class period that arises from the action, including the process and price and the tender offer; the disclosures in connection with the tender offer; legal and fiduciary duties of the released defendant parties in the tender offer; HC2's decision not to consummate a short form merger after obtaining 90 percent ownership of the company's common stock; any lack of liquidity following the non-tender -- following the tender offer in 2014; and claims arising from the settlement,

including the settlement tender offer and the financing of the settlement.

So the release is carefully limited to claims which were squarely at issue in this action when you look at the claims. What's being released is on all four corners with what was alleged and what is at issue in the action. And, again, for claims that were asserted or could have been asserted based on class members' ownership of Schuff shares during the class period.

And I note, Your Honor, just for -- to refresh your recollection, if you need it, that the class period commenced on May 12th, 2014, and ended on November 15, 2019, the date of the stipulation.

So what we're asking from Your Honor today is for three things: class certification, settlement approval, and an award of fees and expenses for the attorneys, as well as a small incentive award to plaintiff. Or I shouldn't say small. An incentive award to plaintiff.

In opposition to plaintiff's motion, two objectors have opposed class certification and approval of the settlement.

With regard to class certification,

- Your Honor, the -- I'm sure Your Honor is fully familiar with Rule 23(a) and Rule 23(b) and what it requires.
- Numerosity and commonality are not disputed here.
- 6 The objectors did take issue with 7 adequacy and typicality. The objectors are wrong. 8 Typicality requires that the class cert 9 representative's claims fairly presents the issues on 10 behalf of the represented class. So "[a] 11 representative's claim ... will suffice if it 'arises 12 from the same event or course of conduct that gives 13 rise to the claims ... of other class members and is 14 based on the same legal theory." And that's from the 15 Leon Weiner case, which I believe Your Honor cited in

your recent Medley decision.

16

17

18

19

20

2.1

22

23

24

Here, plaintiff is a current Schuff stockholder who held shares continuously since before the tender offer. He did not tender any shares in the tender offer and is therefore a non-tendered stockholder. And I note that no tendered stockholders have filed any challenge to the tender offer or sought to intervene in the action, and certainly none of them have objected here. Candidly, they are over-the-moon

thrilled with this result based on the calls that we've received.

2.

Plaintiff's claims, like those of other class members, arise out of the same course of misconduct by defendants, their role in connection with the unfair buyout and failing to ensure that it was entirely fair as to price and process. All their claims are based on the same legal theory. And that is the harm sustained as a result of defendants' breaches of fiduciary duties in connection with the buyout in 2014.

Where one lead plaintiff represents a proposed settlement class that includes stockholders who tendered their shares in the challenged tender offer and stockholders who did not tender, the Court has taken a "pragmatic approach" in certifying the class. That's from Vice Chancellor Laster's decision in the GFI case. In GFI, the Court treated a third-party tender offer and back-end merger as a unitary transaction, as we have contended here, and permitted tendering stockholders to represent a settlement class that included non-tendering stockholders.

And in Blank v. Belzberg, Vice

Chancellor Lamb certified the class and permitted a non-tendering stockholder to serve as a class representative for a settlement class that included tendering stockholders because settlement terms were fair to both groups of stockholders.

Even outside of the settlement context, the Court has taken, again, a practical approach to determining whether or not claims are typical. In the Wiegand v. Berry Petroleum case, the Court certified a class consisting both of stockholders who sold their stock prior to a merger as well as stockholders who continued to hold their shares and were subsequently frozen out in the merger, finding "a class representative may not be identically situated in all respects to other members of the class, [but that] does not mean that his personal interests necessarily conflict with those of the class."

And, again, in the Leon Weiner case, the Court explained that "the question of law linking the class members is substantially related to the resolution of the litigation even though the individuals are not identically situated." And if that's the case, typicality is satisfied.

THE COURT: How many shares does 1 2 Mr. Jacobs hold? 3 MR. ENRIGHT: 300. 4 THE COURT: So I'm open to taking a 5 pragmatic approach with regard to the distinction 6 between the tenderers and the non-tenderers. 7 strikes me is that perhaps we have a Celera problem, where within the non-tendering class Mr. Jacobs has 8 9 different aims than the objectors who hold a larger 10 block of stock. 11 MR. ENRIGHT: Well, Your Honor, there 12 is no -- there is no distinction among shareholders in 13 terms of typicality for their claims based on their 14 investment objectives, okay. The question is whether 1.5 or not their claims are the same. And here, Mr. --16 THE COURT: Drifting us into adequacy 17 a little bit. 18 MR. ENRIGHT: Sure, perhaps. And if 19 you would like, I will move into adequacy, if you 20 But Mr. Jacobs' goal here, and at all times, 2.1 was to obtain fair value for all the stockholders at 22 the time that is defined by the claims, which is as of 23 the 2014, October 2014 time frame. That is the only

claims that could be asserted here. There is no

24

inference, and objectors have pointed to none, that
there is some sort of obligation today for HC2 to cash
out the minority stockholders at the current value.

That is not an option. It's not something that
anybody has indicated that there's any claim that we
could point to that could conceivably force that on
them.

What Mr. Jacobs' whole point here has been to achieve is equal treatment based on the wrongs that were actually committed that we have actual claims on. And that is to obtain fair value at that time.

Now, given that the share price has potentially, and maybe, even, you could say apparently -- or the share value, it's not the share price, has appreciated in the interim, that's why the structure that we chose for the settlement here is a settlement tender offer. So it gives the remaining stockholders the option to tender or not. If they don't like it, they just don't tender. And, again, the only claims they are giving up are claims in connection with this 2014 tender offer which AB explicitly said they don't think that they were harmed by.

Now, that may be because they mostly 1 2 bought their shares after that. But the point is that 3 all it does is provide the optionality. Therefore, 4 that puts Mr. Jacobs and all of the stockholders, not 5 just the non-tendering stockholders -- and all of the 6 stockholders in the same position -- that is, 7 achieving a resolution of this litigation that 8 provides the best outcome in achieving fair value for 9 these shares at the time that's dictated by these 10 claims, which, again, is October 2014. 11 There are not claims that we could 12 possibly -- that I am aware that we could possibly point to, and none of the objectors have pointed to, 13 14 that indicates that there's some claim that we could 15 use to compel them to pay fair value as of 2020. It's just not there. 16 17 THE COURT: I'm just struggling a 18 little bit with the fact that Mr. Jacobs apparently 19 wants a liquidity event. I imagine HC2 and the 20 company want a liquidity event for Mr. Jacobs. 21 the objectors appear not to want this liquidity event. 22 MR. ENRIGHT: So they don't have to 23 take it.

THE COURT: But there's collateral

24

consequences to them, for reasons that we haven't quite gotten into yet -- namely, the source of the payment.

MR. ENRIGHT: Sure. Which is just

De minimis, Your Honor. But that money is going to be coming one way or another. And the collateral consequences to them are so de minimis as to be immaterial. But we will get to that.

THE COURT: Well, can you address just the fundamental tension between the plaintiff representative and the majority of the non-tenderers with whom he is most aligned as to whether or not this liquidity event is something that they even want.

MR. ENRIGHT: Your Honor, I think having a liquidity event is something that, because it's an option, whether they want it or not is sort of immaterial. If they don't want it, they can just decline it.

Mr. Jacobs, candidly, I think he was agnostic as far as whether or not he wanted to liquidate. He wanted to just obtain an availability of fair value for everybody. He agreed to tender his shares here in order to facilitate the settlement.

But he is not -- he's not itching to cash out his

- shares. It's more a matter of he simply wants to

 obtain the best outcome for everybody. And if him

 being -- tendering in the settlement tender offer is a

 requirement for that, then so be it.
- THE COURT: As to Mr. Jacobs

 specifically, to what extent is the second tender

 offer an essential part of this settlement?
- MR. ENRIGHT: Pursuant to the

 stipulation of settlement, this is all a single

 agreement, okay. If any part -- if the settlement is

 not approved or any material part of it is not

 approved, then we don't have a settlement. That's not

 just Mr. Jacobs' position; that's what the stipulation

 of settlement says.
- THE COURT: Well, I asked what his position is.
- 17 MR. ENRIGHT: Oh. We're speaking on 18 behalf of -- Your Honor, we're bound by the 19 stipulation of settlement. So he's certainly 20 required, as part of our litigation tactics and our 21 theory of the case that all of the shareholders were 22 in the same position in that they were all harmed in 23 the same way from the same course of conduct in 2014, 24 so we have required that all the stockholders be

treated equally. And the only way that we could structure a settlement that would provide for everybody to be treated equally was to get the money for the tendered stockholders and give the non-tendered stockholders the option to take this money. If they don't want to, if they want to just sit tight, they could do it. So this takes really nothing of value from them. Again, it's just a release of these 2014 claims. And at least it gives them the opportunity to take the liquidity if they want it.

Now, Your Honor, I would note that given that there is this strong perception that the current value of these shares is higher now than it was then, it makes perfect sense for them to sit tight and keep their shares, if they so choose. But not everybody has that same eventual horizon. And some stockholders may want to take it. And this optionality has a real value to them. It's a guaranteed concrete payment for these illiquid shares that they can take if they so choose. That has a substantial value. And if they choose not to, that's fine too. But what they are giving up is so

De minimis in value that -- in relation to what's

achieved that it is a no-brainer that they should have that option.

2.1

Again, Your Honor, we have achieved everything that could potentially be achieved in connection with these 2014 claims. There's no inference that we could have gotten, and none of the objectors argue that we could have gotten, a better result with regard to our claims arising from the 2014 buyout.

What they say, instead, is, well, the shares are worth more now. But there's no claim here that we could assert to get them that current value. So it's illusory. The claim that -- the argument that they somehow should have gotten more is illusory because we have no mechanism and no claim to get that for them.

All the wrongs here, based on our claims, took place in that 2014 time frame. And this is what the stock was worth then. And we've gotten, essentially, a hundred percent value return for them. Plus the non-tendered stockholders get to keep the \$17.16 per share in dividends that they have received in the interim, which would offset any prejudgment interest almost entirely, if not entirely.

Does that make sense?

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

THE COURT: Yes. Why don't we turn to the source of payment.

MR. ENRIGHT: Okay. If you will bear with me, Your Honor. We're kind of jumping around a bit. I need to take a moment to get organized.

THE COURT: No problem.

MR. ENRIGHT: Okay, Your Honor. With regard to the settlement funding, as part of the settlement negotiations, the parties explored the source of the settlement payment and concluded that the structure was the only workable approach due to specific contractual constraints on HC2, debt covenants. And it's crucial to note that the cost of almost all of the settlement payment will be borne by insurance and indirectly by HC2: 97 percent. 60 percent of the settlement payment to the tendered stockholders is coming from insurance. And the minority stockholders own 7.5 percent of the company, with HC2 owning the other 92 1/2. So that works out, just doing the math, that 7.5 percent of the 40 percent of the settlement payment not coming from insurance, that would, at least theoretically, filter down to the minority stockholders. Simple

31

```
multiplication, 7.5 percent times 40 percent is
 1
 2
    3 percent. It's an immaterial, de minimis amount.
 3
                    THE COURT: It may be that when we run
 4
    the filters and run the math, that the number gets
    small. But I have a problem with sort of the
 5
 6
    fundamental almost morality of it, that in an even
 7
    exchange of consideration between adversaries -- the
 8
    company is not an adversary here -- the adversaries
 9
    are obtaining releases at no cost, other than through
10
    HC2's indirect ownership. That's my issue.
11
                    MR. ENRIGHT: Well, number one, HC2
12
    paid for the insurance policy, okay. That's
13
    60 percent of it right there. 92 1/2 percent of
14
    anything, any cost borne by Schuff will filter down to
15
    HC2. And the other 7.5 percent comes out to $600,000
16
    to the minority stockholders, okay. That's $2 per
17
    share on a stock that the objectors say is worth $132
18
    based on an intercompany transfer of the stock from
19
    2018. That's like 1.5 percent of the value of the
20
    stock. It's immaterial, Your Honor.
21
                    THE COURT: Again, I understand the
22
    math.
23
                    MR. ENRIGHT: Okay. I will move on,
24
    then.
           So --
```

THE COURT: But I'm struggling with --

2 MR. ENRIGHT: Sure. With the equity

of it.

3

4 THE COURT: With the principle.

5 MR. ENRIGHT: Your Honor, the amount

6 | is perfectly reasonable when one considers that Schuff

7 has indemnification and defense cost advancement

8 | obligations to the individual defendants under Section

9 Nine of their charter. Those obligations could easily

10 eclipse the amount that Schuff is paying into the

11 settlement here, okay. The defendants are represented

12 by no fewer than four very capable law firms. The

13 legal expenses alone, and the advancement of those

14 legal expenses, could alone exceed the amount that

15 | Schuff would contribute to this litigation.

16 THE COURT: But that's a separate

17 | bargain that the company strikes with its directors in

18 | choosing who is going to be a director and all these

19 policy reasons of why we have advancement and

20 | indemnification. I see that there's money that comes

21 off the top, as far as the overall resources that the

22 | company would have to pump in to keep this litigation

23 going. But, again, as a matter of principle, it seems

24 | that that's kind of apples and oranges a little bit.

```
MR. ENRIGHT: I disagree, Your Honor.
 1
 2
    Schuff has to exercise its business judgment in
 3
    determining what is in its best interest in terms of
 4
    conserving its resources and applying them most
 5
    effectively for the success of the company.
 6
    Schuff board of directors has decided that this
 7
    settlement is in Schuff's best interest based on
 8
    balancing the amount that it would have to pay under
 9
    this settlement versus the exposure that it bears as a
10
    result of the indemnification and defense cost
11
    advancement obligations that it has.
12
                    THE COURT: Has the board changed from
13
    the directors --
14
                    MR. ENRIGHT: It's mostly the same.
15
    think there's been some minimal change. But I think
16
    most of the members are the same.
17
                    THE COURT: That's something that
18
    struck me about this, is that Schuff isn't here.
19
    are not at the table for the settlement. I don't
20
    actually know, other than your representation just
21
    now, that the board did approve this.
22
                    MR. ENRIGHT: Well, they did. And I
23
    believe that's clearly disclosed in the -- well,
24
    number one, they wouldn't have signed off on this if
```

```
not for the fact that they had board approval.
 1
 2
    number two, I think that's disclosed in the
 3
    offer-to-purchase document. But I'm sure some of the
 4
    defense counsel here who represent some of the
    directors, as well as HC2 and -- I'm sure they will be
 5
 6
    able to speak directly to the mechanism of approval
    that was followed here. But Schuff certainly did
 7
 8
    approve this.
 9
                    THE COURT: I would be curious to
10
    know. We've got directors that are named in this
11
    litigation. Was there a special committee of people
12
    who weren't named who approved this?
13
                    MR. ENRIGHT: I don't know, Your
14
           But, again, I'm sure that they would be able
15
    to address that. But --
16
                    THE COURT: Because going back, that's
17
    another pot of folks who are getting releases that
18
    didn't put anything in.
19
                    MR. ENRIGHT: Sure. But I think the
20
    point is, Your Honor, that -- I don't think there was
21
    a special committee. But the point is, Schuff has --
22
    it's not a question of anybody's business judgment
23
    that Schuff has these indemnification and advancement
```

obligations. And clearing the decks of those will

24

- 1 inevitably provide an enormous benefit to Schuff.
- 2 | There's no question about that, okay. That doesn't
- 3 | take any kind of guesswork. Clearing the decks of
- 4 | this enormous potential liability --
- 5 THE COURT: How does the D&O insurance
- 6 play into that particular risk?
- 7 MR. ENRIGHT: Well, Your Honor, the --
- 8 | there are innumerable potential outcomes as far as how
- 9 the D&O policy could factor into this. But it's
- 10 possible that the D&O policy could be exhausted
- 11 | through litigation. It's possible that the D&O
- 12 | policy -- and that ultimately the full brunt of this
- 13 | would fall on Schuff for its indemnification of the
- 14 defendants and, thus, far, far exceed the very limited
- 15 payment that it's making here, which is 40 percent of
- 16 the settlement fund.
- Moreover, Your Honor, this isn't a
- 18 matter of choice or some sort of scheme. The simple
- 19 reality is this is the only structure that could get
- 20 this case resolved. HC2 is bound by debt covenants
- 21 that prevent it from making a payment along these
- 22 lines.
- THE COURT: I'm wondering how to
- 24 process that. Because if this went to trial, I'm

assuming that a judgment against HC2, they would have to make good on it. So --

MR. ENRIGHT: If we took it to trial and got a judgment, I don't think that would be something that would violate their debt covenants because there would be an order of the Court. I don't think they are allowed to make any kind of discretionary payments like this under their debt covenants. So if it went to trial and there was a judgment, I think that would be reversed.

But in terms of, from the plaintiff's perspective, weighing and balancing those risks, we literally obtained a number here that's higher than our own expert's DCF indicated. Why would we risk that when we can take it and — with no further risk and just give it to our stockholders, give it to our class members? There's no reasonable reason why we would defer that.

19 THE COURT: What else?

MR. ENRIGHT: Okay. So, as I noted,
Your Honor, clearing the decks of these contingent
liabilities arising from the company's indemnification
and defense cost advancement obligations is an
enormous benefit to Schuff. And there's really no way

to avoid that.

Moreover, eliminating this potential risk and liability makes it all the more likely that the minority stockholders will ultimately get an opportunity to realize the current value of their Schuff stock through a sale. Clearing the decks of this contingent liability will make Schuff much more likely to actually be purchased in an upcoming transaction. Again, in light of the fact that on February 10th HC2 announced that they were placing Schuff on the auction block. And I would note, Your Honor, that this is part of sort of a cleaning-house process that's going on right now at HC2. They are liquidating other companies in their portfolio. This is, I think, something that's just going on inside at HC2 in terms of their internal finances, et cetera.

about this three days before the hearing, but the facts are what they are. And by saying I wasn't thrilled to learn about it, I don't mean that it's bad for us. I mean it just required me to do a lot of additional work to figure out what this all means.

But, ultimately, where I land on this is what this means is that the minority stockholders have the

prospect of a potential liquidity event on the horizon -- potential, nothing certain, certainly -- but reaching that point on the horizon is much more likely if the risk and potential liability from this litigation is cleared and they can sell Schuff free of any potential liabilities that any buyer would have to worry about.

And I think, ultimately, that would serve the objectors' best interests more than anything else, to get this resolved and let this company move on. And if they can be sold, great.

I would note, Your Honor, that -- and this is disclosed in the offer to purchase -- a couple years ago HC2 engaged Deutsche Bank to try to sell DBMG at that time. And they found no takers. It is my impression that one of the main reasons why they were unable to find a buyer for the company at that time, despite its outstanding cash flows, is because of the contingent risks that this litigation poses to them. I think clearing the decks of this litigation will serve everybody's interest, the tendered stockholders, the non -- any non-tendered stockholders who wish to tender in the settlement tender offer and the non-tendered stockholders who decline to settle --

to tender in the settlement tender offer. Clearing
the decks of this litigation serves the best interests
of Schuff and its stockholders. I don't think there's
any way around that.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

And, Your Honor, just in terms of this circular transfer payment issue, the case that the objectors point to as saying that it's somehow improper is Gatz v. Ponsoldt. In that case, the company was paying the settlement -- for the settlement, and objectors came along, sort of similar to here, and said, hey, we're just paying ourselves. This is just a circular transfer. The Court approved the settlement because -- after being able to show that only between 7 and 27 percent of the settlement payment was actually being ultimately borne by class members. 3 percent is obviously a lot less than 7 to 27 percent. So I think when you look at Gatz, it's clear that this is not a circular transfer payment. It's a de minimis economic burden on Schuff. provides tremendous value and benefit to Schuff. It's in their interest, and all of the stockholders' interest, regardless of what classification you put them in, to allow this to move forward.

Ginsburg, the Delaware Supreme Court affirmed the approval of a settlement where the company paid into the settlement rather than the board.

So, again, Your Honor, while I understand the sort of gut feeling of saying, hey, why is Schuff paying this and not HC2, the reality is because HC2 literally cannot settle this case and make the payment itself because 60 percent of the money is coming from insurance, which, again, HC2 paid for, and because, ultimately, 92 1/2 percent of any payment made by Schuff will ultimately be borne by HC2.

The idea that this somehow allows

Schuff to -- I'm sorry, HC2 to escape the consequences

of this, it's just not correct, Your Honor. 92 1/2

percent of it would filter down to them in the end.

so in terms of the equities, they are not getting away with something here. They are ultimately paying for this. And that 3 percent left to the minority stockholders, they benefit from the insurance covering a huge portion of this, 60 percent of it, and they benefit from Schuff being freed of those liabilities and being free to move into the future with a clean slate.

So, Your Honor, one thing that Fair

Value noted in their papers was they said, well, look, we would have gotten \$68.99 per share if we had been allowed to do appraisal back in 2014, or if we were allowed to do appraisal now based on the fair value in 2014, and we would get interest, and it would all come out to \$88 and some-odd cents per share.

All those assumptions, frankly, are dubious or just unrealistic. So -- because that assumes that they would have established that they were entitled to appraisal of their shares as of that time as a legal right. A questionable assumption. It assumes that they would have established \$68.99 a share as the fair value at that time. Again, a questionable assumption. And it assumes that they would have borne no costs or legal fees in getting there, which is a completely unrealistic assumption.

So when you look at the net tender offer price here that would be offered if the Court awarded the full fee that we would ask for, which comes out to \$56.56, add the dividends that they received in the interim, which they concede would be an offset, because if they had been liquidated out of the stock five years ago, they wouldn't have gotten all those dividends in the interim, and you add those

```
together and then you subtract a reasonable amount of
 1
 2
    attorneys' fees out of the $88 that they say that they
 3
    would have gotten had this been fully successful, it
 4
    ends up working out to almost exactly the same thing.
 5
    There is no economic disadvantage to any of the
 6
    objectors here from allowing this opportunity because,
 7
    again, Your Honor, we have obtained essentially the
 8
    fair value of what our claims would allow.
 9
                    THE COURT: Thank you. I think I will
10
    hear from Mr. Shindel.
11
                    MR. ENRIGHT: Your Honor, if I could
12
    just address -- do you want to hear from me at all
13
    about the release?
1 4
                    THE COURT: I think we've touched on
    it already.
15
16
                    MR. ENRIGHT: Okay. And in terms of
    fees and expenses, Your Honor, we believe that this is
17
18
    an outstanding outcome, one of the best in the history
19
    of this Court. I think when you look at the
20
    Cornerstone Therapeutics case, our result here
21
    compares very favorably to it, and the 27 1/2 percent
22
    that was awarded there would be appropriate here as
23
    well.
```

Thank you.

THE COURT:

24

1 MR. ENRIGHT: Thank you.

MR. SHINDEL: Good afternoon, Your

3 Honor.

2.1

4 THE COURT: Good afternoon.

the ground that he did.

MR. SHINDEL: I will try to be brief
and address the areas where Your Honor seemed to have
questions for Mr. Enright. I'm not going to retread

With respect to this issue of coercion, a couple of points. The first is, as Mr. Enright did point out, Schuff stock is very thinly traded. I think, just to get some numbers on the record, between January 1st, 2017, and March 31st, 2019, Schuff stock traded between \$32.10 a share and \$45.15 per share, which means that the settlement tender offer payment, even net of the requested fee award, represents a premium between 27 percent and 79 percent of the trading price. And the notion that the objectors, or any other non-tendering stockholders, can be coerced by being given an option is one that's just hard for me to parse. If they don't take the option, you know, they are in the same position they are now.

I think particularly in light of the

announced sale process, the notion of coercion really goes out the window. For those stockholders who want to stay in the stock, collect whatever dividends might be forthcoming, and take the risk of what the outcome of the sale process is, that option is there for them. For those stockholders that would prefer the certainty of the settlement tender offer price and want to take the bird in hand, that option is there for them.

THE COURT: We have a whole body of law on coercive tender offers. What I'm hearing you to say is that that's not a thing. What am I misunderstanding?

MR. SHINDEL: Well, I think the body of law about coercive tender offers in *Pure Resources* and *CNX Gas*, for one thing, they frequently require some type of retributive threat. You know, you're going to be stuck in here no matter what. And that's sort of the exact opposite of what we have in light of the announced strategic alternatives process.

THE COURT: Just something that struck me as being different about -- I mean, the 2014 tender offer was allegedly introduced in connection with a short form merger that was to follow. And there isn't one of those here. And now we've got some other,

perhaps, news on the horizon. We'll see. But it seems that there's fewer options now in connection with the second tender offer.

MR. SHINDEL: Well, I think the -- I don't know that it's true that there are fewer options. I think it's disputed as to whether there was an announced short form merger that was necessarily going to follow. I think there was, perhaps, an intent to do so. But that -- you know, and that would have been part of the litigation here.

We're talking about now a company in which only -- in which HC2 owns 92 1/2 percent of the stock already. The notion that -- the idea of coercive tender offers is you have this prisoner's dilemma problem, where if you don't tender, then you are going to be stuck in the company where there's only 2 or 3 percent in the public float, all right. We are already -- the public float is 7 1/2 percent. So the idea that folks are being coerced because now the public float will only be 5 percent or 4 percent, there's no adverse change in position. When you have a successful coercive tender offer claim, it's because, you know, it's majority public and now it's going to be minority public, and you have introduced a

controller and you are coerced because the controller then can do what he or she or it wants.

That's not the situation here. It's providing them an option. They can take the liquidity event in hand or they can wait. Like I said, if they prefer to get their dividends, if they prefer to wait for the sale process, then great.

So I don't think the structural coercion that those cases talk about is at issue here. You know, I think part of the proof of that, as Your Honor pointed out, the majority of the minority issue. I mean, clearly, these objectors haven't been coerced and cowed and have their hands tied and being forced to take it. They are here objecting. Apparently they don't want to take the option.

THE COURT: I think that's a different calculus. Right now we are at do they want this imposed on the company. I don't think we've gotten to the point of do they actually want to take the tender offer. That's perhaps down the road.

MR. SHINDEL: Well, certainly it's down the road. And they are not foreclosed from taking it just because they are here objecting. But, you know, again, I think it's a perfectly free choice.

There have been ample disclosures around it through the virtual data room. The stockholders are armed with as much information as they could possibly have about whether they want to take that or not. You know, and, again, I think with the potential sale, you know, that's certainly another option. If they prefer to stay in the stock, that's up to them.

But to the point of -- to the point of coercive tenders, I think it's apples and oranges between this situation. There's no change in position if they stay in the stock. And none of the objectors point to any reason why they are allegedly going to be worse off if some proportion of the non-tendering stockholders tender and they choose not to. What the objectors are really attempting to get at is the idea that they want to be bought out for what they believe is, quote/unquote, current fair value.

And as Mr. Enright pointed out, there is no claim in the case for that. There's no precedent for it. The objectors have not tried to intervene to go pursue that claim. And Your Honor raised the question of the alignment of interest. I mean, the named plaintiff, Mr. Jacobs, his interest here is in vindicating the claims that he brought,

which, by and large, this settlement does. It provides equal treatment to the two subclasses. It pays a robust amount. We can debate. I don't have a position on whether it's fair value as of 2014. But that's what it's focused on.

I don't think there's any claim here that HC2 or anyone else can be forced to buy out the existing stockholders now for any particular price, fair value or anything. And, again, in terms of the alignment of interests, I think at least one of the objectors has pursued a course of action over a period of years that demonstrates that his interest is not aligned with the other objectors and his interest is in some type of exchange offer or other buyout whereby his 10 shares and the shares of others that he purports to be able to speak for, who are stockholders of Schuff, can be exchanged into HC2 stock.

Now, he's free to pursue that objective, and serve ten 220 demands, and can monitor this litigation and engage in communications with HC2's counsel, et cetera and so forth. But that is not an interest that's aligned with other objectors or the stockholder class at large.

The issue of round-tripping the

payment and the source of the funding, again, I think it's largely -- it's largely a misnomer because, again, as Mr. Enright pointed out, the amount that's actually borne by class members is de minimis here. You do have 60 percent that's coming from insurance. Of the other 40 percent, HC2 owns 92 1/2 percent of this company. There are ample benefits for Schuff through the settlement. I think Mr. Enright covered them. I'm not going to reiterate them. The only point I'm going to make is the concern, I think Your Honor at one point phrased it as almost one of morality.

The fact of the matter is that in almost every fiduciary case, the company is either not a party or is, at most, a nominal defendant. Right? The defendants are the directors, potentially the officers who are accused of breaching their fiduciary duties for whatever reason.

It is frequently the case that the company contributes to a settlement payment in order to get a settlement done. It's almost always the case that if there's insurance available, insurance is also kicking in. And, you know, in Gatz, in Schwartz, I think in the Zynga settlement, concerns were raised

about round-tripping, and the Court has always, at
least in those cases, has rejected that as being a
reason to quash the settlement. And the fact of the
matter is that the Court, as a policy matter,
encourages settlement, certainly encourages settlement
for monetary value. You know, in the last few years,
I'm sure Your Honor is well aware there's been a
movement in the Court to really hyperscrutinize
disclosure-only settlements and encourage settlements
that provide real cash value and real value, monetary
value to stockholders.

You know, adopting a position that whenever a corporation that is a nonparty or only a nominal defendant funds some portion of a settlement is a reason to reject the settlement is going to make it very difficult, in many cases, to get settlements providing monetary value to the class done.

THE COURT: And I appreciate that.

And I appreciate that oftentimes the pot that's available to wrap things up and to satisfy plaintiffs comes from the company, it comes from D&O insurance.

But it just strikes me as particularly difficult here, where HC2 seems to be gaining the most, particularly in light of this acquisition or sale process that's on

the horizon, that HC2 is able to wrap this up with a bow and then go out and realize more value as a result and get this off the books.

2.1

I'm struggling with the give-get, as opposed to the -- I mean, there's some concerns about, as you call it, round-tripping. But I'm more concerned about the duality of the give-get.

MR. SHINDEL: Well, I understand, Your Honor. I guess what I would say, the sale process, I would submit, should not be a concern, I think. We'll hear from the objectors. I mean, they are focused on getting cashed out for present value. I mean, the sale process, if successful, will accomplish that. Or to the extent it doesn't, you know, they can litigate that in that context, and their voice can be heard in that context if they think that Schuff is being sold for less than its fair value at the time. But presumably that is what they want. So the notion that the sale process in connection with the settlement is providing a windfall for HC2 I don't think is accurate.

THE COURT: That's not quite how I meant it. I meant more that it demonstrates to me or provides context for the significance of this

settlement and the releases that come with it to HC2
in comparison to what HC2 is, out of its own pockets,

putting on the table.

MR. SHINDEL: Well, understood, Your Honor. I would say that, you know, I think in the context of the sale process, again, everybody is aligned there, I would think. You know, in terms of stockholders who continue on, who don't tender, everybody at that point will be aligned in achieving the highest price possible. And although it's not certain, I think it's logical that, absent this settlement, the sale process is not going to achieve what it otherwise would achieve. Does HC2 own the vast majority of Schuff? Yes. I mean, I can't dispute that.

You know, in terms of the give-get here, I don't think -- and I think the Zynga settlement is a good example. You know, the plaintiffs in that settlement focused on my client in that case, Mark Pincus. And there were points in the negotiation where the issue was they wanted Pincus to personally come out of pocket, and he did not. And that was a topic of discussion at the settlement hearing.

The fact of the matter is that the goal of the settlement is not to punish a particular defendant, make them pay what someone, whether it's an objector or otherwise, thinks they, quote/unquote, ought to be paying. The give-get is, is the class receiving sufficient value by virtue of the releases that are being given. And I don't think anybody here seriously disputes that that give-get passes with flying colors.

THE COURT: I think the objectors are disputing just that.

MR. SHINDEL: No, I don't think they really are, Your Honor. I think what the objectors are saying is we should be bought out, you know, for current value. This settlement should somehow involve us being bought out for current value. But, again, there's no legal basis to pursue a claim that would have that result.

So it's all well and good to say that, but, you know, again, they haven't tried to intervene. They are not trying to pursue that claim. I don't think there would be any basis to pursue that claim. And they have issues with the releases that I think, by and large, are easily dealt with. I mean, the

notion that a part of the release operates prospectively to the implementation of the settlement, that happened in Medley Capital, that happened in other cases. It has to happen for any case where the implementation of the settlement is prospective. defendant is going to settle and leave themselves open to further litigation based on the implementation of the very settlement that is supposed to provide complete peace.

The objectors raise complaints about settling unknown claims. That is de rigueur in settlements, happens all the time.

The objectors quibble with the scope of the release and point to <code>UniSuper</code>. I think the fact of the matter is the actual release that was ultimately approved in <code>UniSuper</code> is materially indistinguishable from the release here.

So, you know, I understand the objectors are here objecting, but when you cut through it, I think fundamentally the objection is about they want what they view as current value and current fair value, and that's what the complaint is. There's no way to get there from the claims in this case. And what the release is covering are the claims related to

the 2014 tender offer and the implementation of the settlement.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

So from a traditional perspective, in terms of the give and get, I may stand corrected when they speak, but I really don't think that that is what they are objecting to. Fundamentally, they are complaining about they want current value, and they are raising this round-tripping problem. I certainly understand that, and I know why they are focused on that, but I think upon analysis -- and when Mr. Enright and Your Honor were having a colloquy, you sort of put aside the math issue. And I understand why, and I understand what Your Honor was getting at. But I don't think we can put that to the side and ignore it completely. The fact of the matter is that when it all filters down, the non-tendering stockholders are indirectly bearing a de minimis portion of this. And that's important. And that is basically the Gatz case, that, you know, there is no round-tripping issue at these numbers. The number that's being borne here is smaller than what was at issue in Gatz.

THE COURT: And I appreciate your position on that. Is there anything else that you

```
wanted to add to what Mr. Enright said that's unique
 1
 2
    to your client?
 3
                    MR. SHINDEL: No, Your Honor, not
    unless you have other questions for me at this point.
 4
 5
                    THE COURT: I don't think so.
 6
                    MR. SHINDEL: Thank you.
 7
                    THE COURT: Why don't we take a
 8
    15-minute recess, and then I will hear from the
 9
    objectors.
10
                     (A brief recess was taken from 2:44 to
11
    2:57 p.m.)
12
                    THE COURT: Thank you. Please be
13
    seated. I will hear from counsel for the objectors.
14
                    MR. KRINER: Good afternoon, Your
15
    Honor. Robert Kriner on behalf of Fair Market
    Investments. By the way, thank you very much for that
16
17
    recess.
18
                    Your Honor has Fair Market's objection
    submissions. I don't intend to -- and the replies.
19
20
    And I don't intend to go through them again for Your
2.1
    Honor. I know Your Honor has probably read them.
22
                    The objection is based on many points,
23
    but all of the points come back to the same essential
24
          This action challenged a controller acquisition
    hub.
```

of DBM Global -- and I will use the DBM Global nomenclature because that's the name of the company now and that's the name of the new transaction --challenged the controller acquisition in 2014, which was never consummated with a back-end merger. notion that a unitary transaction was challenged is a myth. There was never a back-end merger consummated. And the current transaction is not a unitary transaction because there's not an acquisition involved in this. The action challenged the controller's

acquisition. The controller was alleged to be self-dealing and paying an unfair price, in breach of its fiduciary duties as the controller. The DBM directors were alleged to have been enabling the self-dealing by the controller.

But in the proposed settlement of this controller breach case, it includes a DBM Global tender offer, funded at least in part with new DBM Global debt, and it includes no back-end merger and requires all stockholders to release all class and derivative claims, whether they tender or not, and the stockholders can't opt out.

So this is a new controller

transaction, self-dealing, at the behest of the controller with an interested board, and for which these parties, the controller and the interested directors, seek this Court's blessing for, with full releases and no scrutiny under the entire fairness test or none of the traditional protections of an independent committee or anything else at play here.

Neither plaintiff nor defendants -and in addition to that, Your Honor, the plaintiff and
defendants want Your Honor to flash back to fair
market value, on this new transaction, back to 2014.
And that's the standard for why this new transaction
is something the claims should be released against,
with no protections.

Neither plaintiff nor defendants have cited any precedent for this structure of a settlement with a new transaction funded by the company, at least in part, under these circumstances. None of the cases do. It's not a merger case with a bump. It's not a controller tender offer that ends up with a renegotiated tender offer. In fact, the MAT Five case, which defendants cite, was a controller tender offer case by Citibank, and the settlement involved an opt-out class. And the non-tendering stockholders

were not required to sign the release that the others did when they tendered their stock.

So none of the cases cited before Your Honor are anything like this. And I'm not aware of any precedent. I'm happy to hear from my friends if there is one. And we're told just recently that this entire structure is because the controller can't pay. That's why it's structured this way. But they could if you went to judgment after trial. And that's the reason why this structure is here.

And meanwhile, the representative plaintiff here will tender and wants a \$25,000 special incentive award. He's not adequate to represent the class here and all of the releases. He's going to tender; he's getting out. He's getting \$25,000. He has no stake aligned with plaintiffs who don't tender into this new tender offer. He just doesn't. He's not adequate. And I don't think I heard my friends explain how he really was.

Now, my friends, plaintiffs and the defendants, they don't really challenge the basic points of the objection. They say, yeah, DBM is paying something, maybe \$20 million, maybe \$2 per share, but that's a small price to pay here. Well,

```
why is that fair? Why is the structure fair at all
 1
 2
    with all of these releases? There's no explanation
 3
    for that. There's no precedent for it.
    Indemnification cases, in deal cases where the
 4
 5
    company's insurance pays, that's completely different.
 6
                    They say, well, the company is now
 7
    looking for buyers. Well, hiring Jefferies, or
 8
    whomever it is, to start conducting exploration,
 9
    that's not a buyer by any stretch that I've ever seen.
10
    The timing is interesting, that somehow this is
11
    providing some certainty of a back end, but none of my
12
    friends have said anything like that. There's not a
13
    unitary transaction involved in this new transaction.
14
                    And, really, this only makes the issue
15
    more palatable about the stockholders who don't tender
16
    or are left in the company. It brings all of these
17
    issues to the fore if they really are conducting a
18
    sale process.
19
                    Oh, they also say there are plenty of
20
    benefits to the company, DBM Global. I don't see
21
    anyone here representing the company. No one even
22
    knows about who approved the thing on behalf of the
23
    board, or really whether it was approved.
```

I was surprised to hear Mr. Enright

24

say a couple of things today. One was, well, I only just learned about the sale process. I didn't know it before. And he was unhappy about it, had to do some rethinking. And he said, well, there are a lot of benefits to the company. I don't know who approved it. I don't know if it was the interested board that's still interested in the releases. I don't know if they did. Well, yeah, of course they did. I'm sure we would have heard already if there had been a special committee of some sort, and Your Honor would have been told that, I'm sure.

So who said it was evaluated in any independent way by the company? All we're hearing is the parties who want to settle this case and get out from under the case, and they're speaking for the company and the board here. And the board, by the way, is not independent.

So that just brings me to summary,
Your Honor. And Your Honor can give me questions.
Fair Market submits that this is a grossly
overreaching settlement of a self-dealing controller
case, and the objection should be sustained and the
release should be modified or an opt-out provided
here.

Fair Market has had discussions with the parties to try to work out something. Those discussions could continue if Your Honor withholds a decision today, gives some time to see if we can come to a mutual understanding about how to restructure this.

1 4

2.1

But that's all I had prepared for Your Honor. And I can answer your questions.

THE COURT: Sure. Thank you.

What is your understanding of the measure of damages or other relief that could have been obtained had this gone to trial, just on the 2014 tender offer?

MR. KRINER: That's -- I think it would have been -- if the action had gone to trial on those original claims, it would have been a coercive tender offer case, and the fact that they had made some promises about a back-end merger that never came to light, and apparently they knew quickly after that they couldn't come to light because -- or couldn't come to fruition because the controller couldn't do a back-end merger.

So I think the damages would be related to tendering stockholders who were damaged by

tendering for something less than fair value; and then 1 2 for people who didn't tender, there would have been 3 some damages resulting from the fact that you ended up 4 in a company that was under the control of the 5 majority and your value was diminished thereby. 6 think that's what the damages on those original claims 7 would be. 8 THE COURT: So does it strike you that 9 2020 fair value is generous, in light of that? 10 MR. KRINER: Oh, that current fair 11 value is much higher, we believe, than it was and 12 would have been back at that time, yes. I think 13 that's true today. 1 4 THE COURT: Comparing the two metrics. 15 So I heard you say that you believe that had we gone 16 to trial back when this was brought, that the 17 non-tenderers would have received some measure of 18 damages for remaining in the company in a diluted 19 manner. 20 MR. KRINER: I think that's right. 21 And I, frankly, don't know, Your Honor, if -- what the 22 value of that claim would be based on anything I've 23 ever done. It seems like the case was going to come

down to a tender offer claim and it having been

24

1 coercive from the start for the *Pure Resources*-type
2 reasons. I think that's what -- that ultimately would
3 have been litigated.

1 4

THE COURT: I'm trying to evaluate what the objectors are asking for in light of what they could have obtained at trial. That seems to be the best metric that I can identify.

MR. KRINER: Back at that time, on those claims -- Your Honor, we're not criticizing that the -- that settlement of the tender offer claim without a release of everything else, and without the new transaction and the burdens on the company, maybe that's a good result for that, flashing back to the value then. We're not challenging that.

We're talking about here's a new transaction. It's another self-dealing transaction. It's not unitary. So -- and the company is bearing the cost of it, yet we all have to release it, and release claims relating to it, and we can't challenge the new transaction, and the parties want Your Honor to basically say I'm blessing this over entire fairness. You don't have to jump through the hoops here.

THE COURT: I see. So your foothold

```
for today's fair value is not in the claims that were
 1
 2
    originally brought?
 3
                    MR. KRINER: No.
 4
                    THE COURT: But it's in the scope of
 5
    the releases with regard to the second tender offer.
 6
                    MR. KRINER: Correct.
 7
                    THE COURT: I understand. Thank you.
 8
                    MR. KRINER: Does Your Honor have
 9
    anything else?
10
                    THE COURT: I don't believe so.
11
                    MR. KRINER: Thank you.
12
                    THE COURT: Thank you.
13
                    MR. MONTEJO: Good afternoon, Your
1 4
    Honor.
15
                    THE COURT: Good afternoon.
16
                    MR. MONTEJO: I don't want to beat a
17
    dead horse on these issues, but I do think my client
18
    sits a little differently than a lot of others.
    Number one, as far as I know, my client may be the
19
20
    largest minority stockholder that remains with the
21
    company today. My client's a value investor, believes
22
    that this company is worth significantly more today
23
    than it was back when this 2014 transaction first
24
    occurred.
```

So there's a couple of things that have been said today that I think it just fits right into this Court's standard of review here. It's the Court's obligation to exercise its independent business judgment. Is this fair and reasonable? Does this make sense; right?

2.1

And, you know, when you look at it from that perspective, I would like to start with the tender offer first. What purpose does it serve? Why is it there? It's an offer that nobody contends is a good deal for anybody. It's — the plaintiffs expressly disclaim the fairness of it. Defendants don't even suggest that it's fair. And now the defendants are even issuing a press release to suggest to everybody that, hey, you would be a fool to take this tender offer now. So who is it that this tender offer is directed at? Who's to be participating in it? Anybody informed? No. Mom and pop out there just looking for liquidity because they want to pass on to the next generation sooner, maybe.

But why should that type of structure, a transaction that would not go unchallenged if it was offered on its own in the marketplace today, would not go unchallenged, why should something like that be

```
structured as part of a settlement in this Court?
 1
 2
                    THE COURT: Is your read on the
 3
    situation that the tender offer is primarily targeted
 4
    at Mr. Jacobs?
 5
                    MR. MONTEJO: It can't be -- if all
 6
    they wanted was Mr. Jacobs' shares, part of the
 7
    stipulation of settlement would have been Mr. Jacobs
 8
    is bought out at -- you know, his 300 shares are
 9
    bought out at the same price as the 2014 payment.
10
                    THE COURT: Isn't that part of it?
11
    Hasn't he committed to --
12
                    MR. MONTEJO: He's committed to
13
    participate in a tender offer. But you don't need a
14
    tender offer to do that. I mean, that could have just
15
    been him selling his shares, could have just been part
    of the settlement. And that would have been reviewed,
16
17
    and the Court would have blessed it, and that's it.
18
    Mr. Jacobs is out. Why does -- why did we need to
19
    bring in a public tender offer by the company?
20
                    THE COURT: I think that would
21
    introduce -- then we would have a bespoke one-person
22
    tender offer in the context of a class action.
23
    think that might be problematic.
24
                    MR. MONTEJO: Well, no. I think that
```

what would have been presented to the Court was, as part of this, you know, he's committed to sell his shares to the company. And the Court can decide whether or not it's fair and reasonable, right.

2.1

But this is a situation where you've got 80 percent of the minority stockholders don't want this tender offer to go forward. And, again, it's structured in a way that if the company was to have attempted to do this outside of these walls, it would be challenged. There's no question about it. It would be challenged.

So I just -- I struggle, just from a common-sense perspective, why are we wrapping this structure into a settlement, and why are we obligating anybody to release it.

So, you know, the other thing that's funny about all of this is that the releases they are asking for in the settlement are redundant to the releases that they're asking for in the transmittal letters of the self-tender, right.

So you don't even -- people are discussing whether this should be opt in or -- you don't even need to think about it. If the company wants to go do a self-tender, they can go do that.

- And they will get the same releases in the transmittal letters, presumably. And, of course, you have got
- 3 case law out there on transmittal letter releases.
- 4 But beyond that, the company can go do that. It
- 5 doesn't need a forced, imposed release relating to the
- 6 tender offer.

17

18

19

20

21

22

23

24

7 And they say, oh, you know, we're 8 releasing claims related to prospective action that 9 the defendants have to take. But this is a very 10 unusual prospective action to be taken as part of the settlement. This is -- it's a coercive tender offer. 11 12 There's no -- there's no question about it that 13 they're using the fact that this company is illiquid 14 to try to get more people to cash out so that, you 15 know, hopefully some day they can reap the benefits of 16 the full fair value of those shares for themselves.

That's what this is all about.

And I don't know why Mr. Jacobs

pressed this issue, because the papers -- defendants

say in the papers that this tender offer, Mr. Jacobs

was insistent on it, suggesting that they would have

been willing to do the settlement without the tender

offer in place, but apparently it was Mr. Jacobs that

refused. That's odd to me. That's strange. I don't

1 understand it, and my client doesn't understand it, 2 which is why we're here.

And I do think it's important, the fact that originally what was being complained about was a controlling stockholder doing a tender offer for shares it didn't hold. Now, the way the settlement is structured, the settlement tender offer is being funded by the company. The company is going into debt for that. Can the company burden that debt financially? Sure. But should it right now? Why is it doing it right now?

And this goes back to the fact that -it's been mentioned that there's no independent board.

I'm not even sure that the company has counsel. It's
unclear to me whether the company is even separately
represented in this. So, I mean, whose business
judgment is being exercised here to decide that this
is the best use of money that the company may borrow
to do a self-tender?

Does anybody participate in the tender? If they're informed, the answer is no. So what does that mean? That means that there's no attorney fees that are going to be accumulating on this self-tender if nobody participates.

That raises another problem, because it's been touted that, look, you know, this payment with respect to the 2014 transaction, right, this is 114 percent of what was paid in that transaction, the best recovery in the history of this Court on a percentage basis.

But, you know, there's -- the other thing that was said today that I think is important is that, at least Mr. Enright mentioned, this is kind of like a distribution of the settlement funds. So where you've set this up in a way where you've got a self-tender, which probably is not going to elicit any participation, right. So the non-tendered stockholders get zero, right. But then the tendered stockholders are going to get \$20.4 million.

Now, is it, at least based on -- I don't know the discovery record. What I know is what was in the papers. Based on what's in the papers, the briefing, does that seem fair? I mean, it's more money than their own expert said the -- said was fair value back in 2014. But what I didn't see from Mr. Clarke was any opinion on what the damage should be, or the measure of damage should be for this other piece of the class that they are trying to shoehorn

into this case. The non-tendered stockholders, what
their measure of damages? How should it be
determined? Is there any precedent on it?

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

I'm not aware of any case from this Court that's gone to trial and the Court has determined what the appropriate measure of damages are for a missed opportunity in liquidity. Is it a viable Maybe. You know, maybe it posed some risk. claim? But how do you measure those damages? What should -so there's no information about that. And it's almost as if there's just -- and they say, well, we're treating everybody equally because they're getting the same amount of money. I mean, that would make sense if we stood at the same point in time. But we don't. There's 500-some thousand shares that's standstill in 2014. And then there's 289,000 shares that have moved forward to today.

And it's not the same company as it was back in 2014. The defendants point out, they're doing better because they have implemented a better business plan. This is *Technicolor* all over again, the Perelman plan. When those minority stockholders that aren't cashed out immediately in the second step, right, the value from the date of the first step until

the second step, whenever that occurs, accrues to the benefit of the minority too. They share pro rata in that.

So to say that the 2014 aspect of the class stands equally in terms of value with the 2020 stockholders of the company is ridiculous. It's absurd. But that's what they're doing. They -- so from a logical perspective, this settlement, and the approach to it, is just fundamentally unsound. It has no rational basis.

It would be one thing if they came in to the Court and said, look, we got \$68 per share for the 2014 stockholders. We're going to pay that out. Yada yada yada. And we're going to release the claims for the lack of liquidity aspect of the case dating back to 2014 because we can't justify an allocation, an appropriate allocation between those two parts of the class, right. That would be a reasoned and rational way to come about it. They've got

Mr. Clarke, who says this about one aspect. They will have Mr. Clarke say this about the other aspect. And they would say, Your Honor, this is why our allocation of these proceeds is fair and reasonable.

But that's not what's happening here.

There's no effort to try to rationalize how the funds are being allocated, and it's hard not to lose sight of the fact that the way that the funds are being allocated maximizes the attorney fees that are being awarded.

So adequacy and typicality of the class, I don't think you can get there. The current stockholders stand in a very different place. They don't have claims relating to being unfairly cashed out. They never had those claims, right. They had maybe some other claims, some derivative aspect of that of not being entitled to a liquidity event. And, you know, that's a tough — this is a tough claim to row, right. I mean, that's not a — that's not an easy — at least as far as I'm aware, it's not like you've got a 30-page footnote of cases that you can point to to support that claim.

So it's you are trying to shoehorn in the current stockholders into a class that -- look, I mean, if -- it's a recovery. If it's appropriate and fair for the 2014, it's a fantastic result for them, right. I mean, sure. That's great. Well done.

But -- and then the only question my client has about that is the circularity of it, right.

And the points have been made today -- and this wasn't clear in the stipulation of settlement as it was originally put forth as to where the funds were coming from. That was a big concern for my client.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

So it's been represented now that most of the funds are either coming from insurance proceeds or, arguably, indirectly from the controlling stockholder because of his 92 percent holdings in the company, which leaves us, and I think Mr. Enright said, about \$608,000. Which the problem with that -and this is where we get into the Gatz case. I mean, I think it was Chancellor Chandler. Off the top of my head, I can't remember, Your Honor. I apologize. he didn't say that circularity isn't a problem because here it's de minimis. After supplemental briefing, he determined that, well, the circularity is okay here because there were viable advancement and indemnification claims, up to \$3 million, I think, in that case, against the company. So exercising my independent business judgment, I think it's fair and reasonable for the company to contribute to just end this, right.

But, you know, what's very unclear -- and it's a very short opinion. It's off of

supplemental briefing on a settlement hearing. Very unclear in that case, as opposed to here. I mean, here, it doesn't seem like we have got company's counsel present. We certainly don't have an independent board. Is it okay -- and I don't even know who owns the D&O policy. They say that HC2 paid the premiums on it. But it's the policy and asset of the company? I have no idea. It's unclear from the papers.

2.1

If it's an asset of the company just because HC2 paid the premiums on it, is it appropriate for that asset to fund the settlement? That seems like a different question than if it's HC2's asset under its own parent company, right. That would be a different animal.

So there's \$13.7 million coming from the insurance policy that's going towards the settlement payment. And if that actually is an asset of the company's insurance policy, you know, is it appropriate for the company to be carrying the full burden? Whether it's insurance money or not, it would be carrying the full burden of this settlement payment. And why would that be, when presumably the defendants -- I mean, the plaintiffs claim it was a

slam-dunk case for them, that the arguments made in 1 2 the briefs are very compelling. And why would HC2 not 3 fund the settlement or any aspect of the settlement? 4 And, again, maybe that's answered with 5 a simple question to Mr. Shindel. Maybe it's HC2's 6 insurance policy, and that's -- maybe -- perhaps you 7 can answer that right now. I don't know. The point 8 is that it was after supplemental briefing on all of 9 these points that ultimately this circular issue was 10 It wasn't because it was de minimis. 11 was because after the briefing the Court determined 12 that it was appropriate in that circumstance for the 13 company to contribute towards the settlement funding. 14 Finally, Your Honor, just on the 15 opt-out, I think it's been at least 50 times today 16 that both plaintiff and defense counsel has mentioned 17 options, right. This is just optionality for the minority stockholders. If they don't want it, who 18 19 cares? I mean, isn't that what opt-out class 20 definitions are all about? 21 And the only case, the only case that 22 has been cited that is remotely similar, where a 23 settlement structure that's proposed here is even

remotely similar, involved a certification under an

24

```
opt-out class. So I'm not aware of any instance where
 1
 2
    a non-opt-out class was certified that forced minority
 3
    stockholders to release claims associated with a
 4
    tender offer being driven by a controlling
 5
    stockholder. I'm not aware of any structure like
 6
    that. And if I'm wrong, I apologize to the Court.
 7
                    That's all I have, unless the Court
    has any questions, Your Honor.
 8
 9
                    THE COURT: No, I don't. Thank you.
10
                    MR. MONTEJO: Great.
11
                    THE COURT: Would counsel for the
12
    individual defendants like to say anything? You don't
13
    have to.
1 4
                    MR. LADIG: No.
15
                    THE COURT: All right. Thank you.
16
                    Well, I think it's probably clear that
17
    I have some concerns about all of this. I have
18
    concerns about the date span. I have concerns about
19
    the plaintiff's adequacy to represent everyone -- in
    particular, the non-tendering stockholders. I have
20
21
    concerns about the give-get in light of where the
22
    funds are coming from. I have concerns about the fact
23
    that the company is not here, nor do I know the terms
24
    under which the company has approved the settlement.
```

- And I am concerned about the non-tendering 1 2 stockholders receiving fair consideration for their 3 releases.
- It seemed to me that Mr. Kriner raised the possibility that perhaps further discussions could 6 take place now that the objectors are here in the 7 room. And so I'm wondering if that is something that 8 you would all like to engage in -- it would make me 9 more comfortable if there was some form of independent 10 representation from the company, as well, in those 11 conversations -- or if you would like to stick to your 12 guns and submit this as presented?
 - So I don't know if you want me to take a recess and you can talk about it. Do you want to do that?
- 16 All right. Just let Mr. Barnaba know 17 when you are ready for me to come back.
- 18 (A brief recess was taken from 3:28 to 19 3:45 p.m.)
- 20 THE COURT: Please be seated.
- 2.1 Who would like to share with the class
- 22 what you have all been discussing?
- 23 MR. ENRIGHT: Your Honor, Donald
- 24 Enright again.

4

5

13

14

1.5

```
First, objectors' counsel and counsel
 1
 2
    for the parties have discussed in the hall, and we
 3
    agree that it makes a sense for us to at least take a
 4
    period of time to confer amongst ourselves, see if
 5
    there's something that can be done to satisfy the
 6
    concerns of the Court as enunciated, see if the
 7
    objectors' concerns can be allayed somehow, and then
 8
    come back to Your Honor with an update in two weeks,
 9
    if that's acceptable to Your Honor.
10
                    THE COURT: That sounds great.
11
                    MR. ENRIGHT: And I don't know if
12
    you -- a lot was said by the objectors here today that
13
    I disagree with vehemently. If Your Honor would give
14
    me a couple of minutes to preserve the record on those
15
    points --
16
                    THE COURT:
                                Sure.
17
                    MR. ENRIGHT: -- I would like to.
18
    at the same time, I don't want to belabor anything if
19
    we're going to just be back here in another hearing
20
    anyway.
21
                    THE COURT: I understand that there
22
    may be things you feel you need to say.
23
                    MR. ENRIGHT: Okay. As a first
24
    measure, Your Honor, there is no reasonably
```

conceivable outcome here that could have been achieved on these claims that's significantly better than what we achieved here. I firmly believe that. We fought tooth and nail over this for years. And I cannot conceive of an outcome of the claims that were actually asserted on behalf of the class here where a better outcome can be obtained. Based on the contemporaneous valuations of the company and our own expert, we've obtained full value for these claims at that time, or the closest thing to it.

That is an enormous value to this class, both the tendered and non-tendered. And to hear this -- that we've worked on very hard. To hear this denigrated here today has been very difficult for me to endure, candidly.

Mr. Jacobs was exceptionally attentive to this case and exceptionally devoted to this case, with one principle in mind. And that is getting fair treatment and equal treatment for all of the stockholders, those who tendered and those who didn't. To hear him called an inadequate plaintiff, after the amount of time and attention and effort he's put into this case, is offensive to me. He has tried very hard to reach the best outcome imaginable, or at least

available for the class, as have we.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

And the reality is, Your Honor, the fact that this short form merger never happened, even though HC2 undertook repeatedly to do it, it threw the monkey wrench into this case that has made structuring a settlement really difficult. This is not a run-of-the-mill case. It has this weird wrinkle in the facts that makes structuring any resolution for it very unusually difficult. And that's why we've had to try to be innovative in trying to come up with a structure that can provide the optionality to the non-tendered stockholders, while at the same time we're not pushing them out of the stock that they might want to remain in, and providing equal treatment for all of the stockholders, while at the same time obtaining, as I said, outstanding value for them based on the claims that we actually have.

And, Your Honor, the issue of coercion here, as I stated before, the minority stockholders will be in no different position before and after this settlement tender offer if it goes forward. And because it's been -- the -- there has been no criticism about the quality of the disclosure in connection with the proposed settlement tender offer.

It is extremely candid about the valuation -
valuations of the company and about the fact that it's

not intended to represent the current full value of

the company.

Given the candid disclosure that's provided, and the fact that they have announced that there is a possible other transaction on the horizon -- possible, no promises -- I don't see how anybody could call that coercive.

And, Your Honor, you've expressed some concerns about the give and the get here. The give and the get, in looking at a -- the fairness of a settlement from the Court's perspective is the give and the get from the plaintiff -- from the plaintiff class. What is the plaintiff class giving and what are they getting.

And, Your Honor, you seem to be focused on the give and the get for HC2. Candidly, Your Honor, that's not the question before the Court today. The question, in determining if the settlement is fair and reasonable and adequate, is whether the give and the get for the class is fair to the class. We're not here to punish HC2. We're here to obtain a fair outcome for the class. And as I said, Your

Honor, I cannot conceive of a significantly better
outcome that could be obtained here than what we've
achieved.

Mr. Kriner said that the unitary transaction is a myth and it's not a thing in this case. That's wrong. And the reason for that is, as laid out very, very exhaustively in our amended complaint, we strenuously contend that HC2 had an obligation to complete the short form merger based on the circumstances at the time and all of the undertakings and promises it made to the stockholders. So it is, essentially, a constructive unitary transaction.

But if it wasn't, and Mr. Kriner was right, then the value of the release that they're giving up in connection with this 2014 transaction is zero. So the give and the get cannot possibly favor the objectors' position because the release that they're giving up in connection with that 2014 transaction is valueless. Any value in the settlement that surpasses that zero would make it fair.

And, Your Honor, something that I haven't had a chance to emphasize is that, if nothing else, the non-tendered stockholders have gained

tremendous information about the company's current 1 2 status that they simply did not have before. All of 3 their objections are based on information gleaned from 4 the offer to purchase. They didn't know anything 5 about any of these valuations of the company or these 6 intercompany transfers or what this company was worth 7 at any point before this information was made 8 available to them by our efforts. That is a 9 substantial value, particularly if this company is on 10 the auction block, as HC2 said on February 10th. 11 Being forearmed with that information about the recent 12 valuations of the company, that is invaluable to them. 13 And that should be taken into consideration as part of 1 4 the value proposition here. 15 And then with regard to this notion 16 that this settlement tender offer should be subject to 17 the Pure Resources/CNX course of tender offer analysis, Your Honor, the whole point here is that 18 19 this is simply a mechanism to make settlement 20 consideration available to these people on an optional 2.1 basis. 22 If there's no actual coercion, and the 23 Court reviews it and determines that this is a fair

settlement -- the Court doesn't have to determine that

24

this is a fair value for the stock today. All the
Court has to conclude is that this is a fair
settlement to allow this full disclosure to be made so
that the non-tendered stockholders can accept or
reject the consideration at their option.

2.1

And I note further, Your Honor, that, once again, the objectors here continue to buy the stock. AB was continuing to buy the stock in 2019. The notion that they're not comfortable being a minority stockholder in this company is simply not credible given the fact that the whole time that they've been buying it they have been a minority stockholder in a super majority controlled company.

THE COURT: Is there anything else in particular that was raised in your friends' presentation that you didn't get a chance to address the first time?

MR. ENRIGHT: With regard to the release, Your Honor, I would just note that it is carefully confined to the facts and allegations and claims in the action. This is not like *UniSuper*, where any tangential, conceivably, imaginably attached or connected items are being released here.

If you review the release here, Your

Honor, it's very clear that it's confined in scope in 1 terms of it's limited to claims that the class members 2 3 asserted, or could have asserted, based on ownership 4 of Schuff common stock during the class period, which 5 ended on November 15th, arising from allegations at 6 issue in the action, including the specific points 7 that were at issue in the action. It doesn't give 8 some intergalactic release. It very carefully 9 enumerates the different issues that were at issue in 10 this action and releases claims based on it. 11 I think that's it. Thank you, Your 12 Honor. 13 THE COURT: Thank you. 14 I appreciate you all being open to 15 tinkering with this further, and I will look forward 16 to getting a status update in two weeks. 17 We're adjourned. 18 (Court adjourned at 3:56 p.m.) 19 20 21 22 23 24

CERTIFICATE

I, DEBRA A. DONNELLY, RMR, CRR,

Official Court Reporter for the Court of Chancery of
the State of Delaware, do hereby certify that the
foregoing pages numbered 3 through 87 contain a true
and correct transcription of the proceedings as
stenographically reported by me at the hearing in the
above cause before the Vice Chancellor of the State of
Delaware, on the date therein indicated.

IN WITNESS WHEREOF I have hereunto set my hand at Wilmington, Delaware, this 17th day of February, 2020.

16 /s/ Debra A. Donnelly

Debra A. Donnelly, RMR, CRR
Official Chancery Court Reporter
Registered Merit Reporter
Certified Realtime Reporter